Shenzhen YHLO Biotech Valuation

Q: What is the Fair Price of 688575 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

688575 (CN¥20.49) is trading above our estimate of [[fair value]] (CN¥7.48)

Is 688575 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 688575 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 688575 (CN¥20.49) is trading above our estimate of fair value (CN¥7.48)

Significantly Below Fair Value: 688575 is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 688575?

Other financial metrics that can be useful for relative valuation.

The above table shows the n/a ratio for 688575. This is calculated by dividing 688575's market cap by their current preferred multiple.
What is 688575's n/a Ratio?
n/a	0x
n/a	n/a
Market Cap	CN¥11.66b

688575 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	6x
Enterprise Value/EBITDA	24.5x
PEG Ratio	1x

Price to Earnings Ratio vs Peers

How does 688575's PE Ratio compare to its peers?

The above table shows the PE ratio for 688575 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	56.8x
300633 SonoScape Medical	32.4x	24.0%	CN¥11.5b
688198 Beijing Balance Medical TechnologyLtd	127.4x	38.0%	CN¥13.5b
301363 MeHow Innovative	45.6x	32.3%	CN¥11.0b
688301 iRay Technology	21.7x	26.8%	CN¥12.8b
688575 Shenzhen YHLO Biotech	30.2x	30.7%	CN¥11.7b

Price-To-Earnings vs Peers: 688575 is good value based on its Price-To-Earnings Ratio (30.2x) compared to the peer average (56.8x).

Price to Earnings Ratio vs Industry

How does 688575's PE Ratio compare vs other companies in the CN Medical Equipment Industry?

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	23.4%
	n/a	n/a	n/a

Fetching data

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	23.4%
	n/a	n/a	n/a

No more companies

Price-To-Earnings vs Industry: 688575 is expensive based on its Price-To-Earnings Ratio (30.2x) compared to the CN Medical Equipment industry average (27x).

Price to Earnings Ratio vs Fair Ratio

What is 688575's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

688575 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	30.2x
Fair PE Ratio	28.3x

Price-To-Earnings vs Fair Ratio: 688575 is expensive based on its Price-To-Earnings Ratio (30.2x) compared to the estimated Fair Price-To-Earnings Ratio (28.3x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 688575 forecast and predictions for the stock price in 12 month’s time.
Date	Share Price	Average 1Y Price Target	Dispersion	High	Low	1Y Actual price	Analysts
Current	CN¥20.49	CN¥27.39 +33.7%	10.2%	CN¥31.61	CN¥24.47	n/a	5
Sep ’25	CN¥20.36	CN¥28.19 +38.4%	10.1%	CN¥31.61	CN¥24.47	n/a	5
Aug ’25	CN¥18.71	CN¥30.22 +61.5%	2.7%	CN¥31.61	CN¥29.56	n/a	4
Jul ’25	CN¥23.26	CN¥30.22 +29.9%	2.7%	CN¥31.61	CN¥29.56	n/a	4
Jun ’25	CN¥24.29	CN¥30.22 +24.4%	2.7%	CN¥31.61	CN¥29.56	n/a	4
May ’25	CN¥23.98	CN¥28.67 +19.5%	8.0%	CN¥31.61	CN¥25.34	n/a	4
Apr ’25	CN¥24.19	CN¥29.50 +21.9%	4.5%	CN¥31.00	CN¥27.77	n/a	3
Mar ’25	CN¥26.09	CN¥29.39 +12.6%	5.5%	CN¥31.00	CN¥27.77	n/a	2
Feb ’25	CN¥21.18	CN¥26.39 +24.6%	5.2%	CN¥27.77	CN¥25.00	n/a	2

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.